Ariela Katz

The FDA has granted the PARP inhibitor Rubraca (rucaparib) a breakthrough therapy designation for single-agent use in adult patients with BRCA1/2-positive metastatic castration-resistant prostate cancer (mCRPC) following at least one androgen receptor–directed therapy and taxane-based chemotherapy.

When given neoadjuvant chemotherapy before getting a radical cystectomy, patients with the basal subtype of muscle-invasive bladder cancer (MIBC) saw significantly improved overall survival (OS) compared to those who had a cystectomy alone, according to a recent study.

For patients with advanced disease, median survival was improved.

An antibody–drug conjugate is being tested in patients with platinum-resistant ovarian cancer.

A clinical trial will test whether partial prostate ablation matches radical prostatectomy in effectiveness — with fewer early side effects.

After a drop, the frequency of PSA screening for prostate cancer has stabilized.

Study: To prolong survival in early-stage prostate cancer that is low-risk, observe instead of operating.

A targeted drug for women with ovarian cancer may also benefit men with prostate cancer who have similar genetic mutations. A phase 3 trial is designed to find out.

Selinexor (KPT-330), a small-molecule inhibitor with a novel mechanism of action, is being investigated in patients with multiple myeloma (MM) who have become refractory to the many new options that have been introduced in recent years for patients with the malignancy.

A study pairs an IDO inhibitor with PD-1 checkpoint blockade.

Clinical trials are a crucial aspect in deciding therapies for patient populations with high-risk melanoma.

Inhibiting the ABCB1 gene with antiandrogen therapy – such as Xtandi (enzalutamide) and Casodex (bicalutamide) – may be the answer to increasing efficiency of tanxane-based therapies.

When used as a neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC), split-dose of gemcitabine and cisplatin has a beneficial response and a high safety profile, according to a study presented at the 2017 American Urological Association Annual Meeting.

Previously reported declines in prostate-specific antigen testing have not continued in recent years, and that approximately one-third of men age 50 years or older still receive routine PSA tests.

The investigational compound targets overexpressed folate receptor-alpha.

One company's production of a popular bladder cancer therapy is set to halt by mid-2017, generating worries from patients and oncologists that there will be a shortage.